T1	SectionAnnotate 82 109	History of Present Illness:
T2	SectionAnnotate 2944 2965	Past Medical History:
T3	SectionAnnotate 3462 3484	Past Surgical History:
T4	SectionAnnotate 4150 4165	Family History:
T5	SectionSkip 4436 5626	Current Outpatient Prescriptions   Medication Sig Dispense Refill    acetaminophen (TYLENOL) 325 mg tablet Take 2 tablets (650 mg total) by mouth every 4 (four) hours as needed for Pain or temp > 38.5 C. 60 tablet 0    acetaminophen (TYLENOL) 500 mg tablet Take 1 tablet (500 mg total) by mouth every 6 (six) hours as needed for Pain. 60 tablet 0    ascorbic acid (VITAMIN C) 500 mg tablet Take 500 mg by mouth every other day.       atenolol (TENORMIN) 25 mg tablet Take 25 mg by mouth every morning.       docusate sodium (COLACE) 100 mg capsule Take 1 capsule (100 mg total) by mouth Twice a day. 60 capsule 0    gabapentin (NEURONTIN) 300 mg capsule Take 1 capsule (300 mg total) by mouth 3 (three) times daily. 90 capsule 0    ibuprofen (ADVIL,MOTRIN) 600 mg tablet Take 1 tablet (600 mg total) by mouth every 6 (six) hours as needed for Pain or temp > 38.5 C. 60 tablet 0    multivitamin tablet Take 1 tablet by mouth Daily. Daily packet multi vitamin      omeprazole (PRILOSEC) 20 mg capsule Take 20 mg by mouth every morning.       simvastatin (ZOCOR) 20 mg tablet Take 20 mg by mouth nightly at bedtime.        No current facility-administered medications for this visit.
T6	SectionAnnotate 5635 5650	Social History:
T7	SectionAnnotate 6076 6094	Review of Systems:
T9	SectionSkip 6840 8130	Physical Exam   Vitals reviewed.  Constitutional: She is oriented to person, place, and time. She appears well-developed and well-nourished. No distress.   Older woman, non-toxic, accompanied by daughter   HENT:   Head: Normocephalic and atraumatic.   Mouth/Throat: Oropharynx is clear and moist. No oropharyngeal exudate.   Eyes: EOM are normal. Right eye exhibits no discharge. Left eye exhibits no discharge. No scleral icterus.   Neck: Normal range of motion. Neck supple.   Cardiovascular: Normal rate, regular rhythm, normal heart sounds and intact distal pulses.  Exam reveals no gallop and no friction rub.    No murmur heard.  Pulmonary/Chest: Effort normal and breath sounds normal. No respiratory distress. She has no wheezes. She has no rales.   Abdominal: Soft. Bowel sounds are normal. She exhibits no distension. There is no tenderness. There is no rebound and no guarding.   Musculoskeletal: Normal range of motion. She exhibits no edema, 
 tenderness or deformity.   Neurological: She is alert and oriented to person, place, and time. No cranial nerve deficit. Coordination normal.   Skin: Skin is warm.   Well-healing post-mastectomy scars, no erythema or fluctuance, not TTP   Psychiatric: She has a normal mood and affect. Her behavior is normal. Thought content normal.
T12	SectionAnnotate 9474 9485	IMPRESSION:
T14	SectionSkip 12350 18439	FINAL PATHOLOGIC DIAGNOSIS  A. Right breast, simple mastectomy:   1. Atypical ductal hyperplasia.  2. Lobular carcinoma in situ and atypical lobular hyperplasia.  3. Papilloma, usual ductal hyperplasia, apocrine metaplasia, and duct  ectasia.  4. Micocalcifications in association with benign ducts.  5. Benign skin and nipple.    B. Left breast, simple mastectomy:  1. Invasive ductal carcinoma, multifocal, SBR grade 2 and 1, largest  focus 3.9 cm, margins negative; see comment.  2. Ductal carcinoma in situ, intermediate nuclear grade, mixed  cribriform, micropapillary, solid and papillary patterns with comedo  necrosis, margins negative.  3. Papilloma, usual ductal hyperplasia, radial scar, apocrine  metaplasia, cysts, and duct ectasia.  4. Metastatic carcinoma to two lymph nodes (2/2), 1.5 cm largest  deposit.  5. Biopsy site changes.  6. Microcalcifications in association with ductal carcinoma in situ and  benign ducts.  7. Skin and nipple with no tumor.    C. Left axillary level 1 and level 2 contents, dissection: No tumor in  ten lymph nodes (0/10).    D. Left breast skin, excision: Benign skin.    E. Right breast skin, excision: Benign skin.    COMMENT:  For the left mastectomy specimen (part B), two lesions are 
 identified  grossly. The first lesion (designated as lesion #1 in the gross  description) is in the lower central breast, measures 3.0 cm and is  associated with a biopsy clip. This lesion shows a single continuous  invasive ductal carcinoma microscopically, spans slices 9 to 11 and  measures 3.0 cm (tumor #1 in the synoptic comment). The second lesion  (lesion #2) is superior to lesion #1 and appears multinodular grossly in  slices 7 to 11. Extensive and sequential sampling of lesion #1 shows  extensive DCIS with three separate foci of invasive carcinoma:  designated as tumors #2 to 4 as in the synoptic comment. Tumor #2 is in  slice 7 and tumor #3 in slices 9 to 11, separated by slice 8, which  shows DCIS without invasion (slides B7 and B26). Tumor #1 and tumor #3  are separated by 1.8 cm of DCIS as in slide B9. Tumor #4 is in ***** 9  and is 0.8 cm away from tumor #3 as in slide B10.     Tumors #1 to 3 have overall similar morphology and are of SBR grade 2,  while tumor #4 has different morphology and is of SBR grade 1.     Breast Tumor Synoptic Comment   - Laterality: Left.   - Invasive tumor type: Invasive ductal carcinoma, four foci, summarized  as follows:  Tumor #1: 3.0 cm (lower central, corresponding to the lesion that was  biopsied in *****-*****. Slides B8, B21 and B24. Slices June 13, tumor size  based on gross measurement)  - Invasive tumor grade (modified Scarff-Bloom-Richardson): SBR grade 2    - Nuclear grade: 2 points.    - Mitotic count: 12 mitoses / 10 high power fields, 2 points.    - Glandular/tubular differentiation: 3 points.    - Total points: 7 points = grade 2.  Tumor #2: 0.9 cm (inner central, superior medial to tumor #1, slide B6,  slice 7, tumor size based on the slide B6)  - Invasive tumor grade (modified Scarff-Bloom-Richardson): SBR grade 2    - Nuclear grade: 2 points.    - Mitotic count: 2 mitoses / 10 high power fields, 1 point.    - Glandular/tubular 
 differentiation: 3 points.    - Total points: 6 points = grade 2.  Tumor #3: 3.9 cm (central to outer, superior to tumor #1 and lateral to  tumor #2, slides B14, B22, B23, B25, slices ***** *****, tumor size based on  involvement of 3 tissue slices)  - Invasive tumor grade (modified Scarff-Bloom-Richardson): SBR grade 2    - Nuclear grade: 2 points.    - Mitotic count: 14 mitoses / 10 high power fields, 2 points.    - Glandular/tubular differentiation: 3 points.    - Total points: 7 points = grade 2.  Tumor #4: 0.2 cm (central, slide B10, tumor size based on slide B10)  - Invasive tumor grade (modified Scarff-Bloom-Richardson): SBR grade 1    - Nuclear grade: 2 points.    - Mitotic count: 1 point.    - Glandular/tubular differentiation: 1 point.    - Total points: 4 points = grade 2.    - EIC (extensive intraductal component): Present.  - Lymphatic/vascular invasion: Not identified.  - Skin/nipple: Not involved by tumor.  - Skeletal muscle: No skeletal muscle present.  - Margins for invasive tumor: Negative: 0.6 cm to the closest anterior  inferior margin (slide B24) and > 1 cm away from all other margins.       - Ductal carcinoma in situ (DCIS): Present.  - DCIS nuclear grade: Intermediate.  - DCIS architectural patterns: Mixed cribriform, micropapillary, solid  and papillary patterns.  - Necrosis in DCIS: Comedo necrosis present.  - Ductal carcinoma in situ size: Present in 6 contiguous slices (slices  7 to 12), spanning 7.8 cm.   - Microcalcifications: Present in association with DCIS and benign ducts.  - Resection margins for DCIS: Negative, >1 cm away from all margins.  - Lobular carcinoma in situ: Not present.  - Non-neoplastic breast: Papilloma, usual ductal hyperplasia, apocrine  metaplasia, and duct ectasia.  - Lymph node status: Positive:      - Total number of nodes examined: 12.      - Total number of nodes with micrometastases: 0.      - 
 Total number of nodes with macrometastases: 2.      - Size of largest metastasis in node: 1.5 cm.      - Extranodal extension: None.    - AJCC/UICC stage: pT2(m)N1a.    - Tumor biomarker (ER/PR/HER2/Ki-67) status:   Immunohistochemical tests for estrogen and progesterone receptors, HER2  and Ki-67 were performed by manual morphometry on block ***** (tumor #3,  the largest tumor).    The test for estrogen receptors is positive. There is strong nuclear  staining in >95% of tumor cells. Internal positive control is present,  and external positive control is appropriate.    The test for progesterone receptors is positive. There is strong  nuclear staining in >95% of tumor cells. Internal positive control is  present, and external positive control is appropriate.    Result of HER2 test: This carcinoma is equivocal for HER2 oncoprotein  over-expression. The staining intensity of this carcinoma was 2 on a  scale of 0-3.    Ki-67 proliferation index: 20 to 30%      08/18/2017 HER2 Gene Amplification Testing by FISH  LABORATORY PHYSICIAN
T15	SectionSkip 18810 20719	FINAL PATHOLOGIC DIAGNOSIS  Left breast, ultrasound-guided core biopsy:   1. Invasive ductal carcinoma; see comment.  2. Ductal carcinoma in situ, intermediate nuclear grade, cribriform  pattern with focal comedo necrosis.   3. Microcalcification associated with ductal carcinoma in situ.     COMMENT:  Breast Needle Core Biopsy Tumor Synoptic Comment    - Invasive tumor type: Invasive ductal carcinoma.  - Invasive tumor size: 1.2 cm longest dimension in one core, with tumor  present in multiple 
 cores.  - Invasive tumor grade (modified Bloom-Richardson): Final grading  should be based on excision specimen.     - Nuclear grade: 2 points.    - Mitotic count: July 12 HPF, 2 points.    - Glandular/tubular differentiation: 2 points.    - Total points/grade: 6 points= grade 2.  - Lymphovascular invasion: Not identified.  - Ductal carcinoma in situ: Present, cribriform pattern with comedo  necrosis.   - Ductal carcinoma in situ nuclear grade: Intermediate.  - Microcalcifications: Present, associated with DCIS.  - Lobular carcinoma in situ: Not present.    The test for estrogen receptors is positive. There is strong nuclear  staining in 100% of tumor cells. Internal positive control is present,  and external positive control is appropriate.    The test for progesterone receptors is positive. There is moderate to  strong nuclear staining in >95% of tumor cells. Internal positive  control is present, and external positive control is appropriate.    Result of HER2 test: This carcinoma is negative for HER2 oncoprotein  over-expression. The staining intensity of this carcinoma was 1 on a  scale of 0-3.    Ki-67 proliferation index: ~20%      06/20/2017 FNA L Axillary Node  Source of Specimen: Left axillary lymph node, fine needle aspiration    FINAL CYTOLOGIC DIAGNOSIS:  A. Lymph node, left axillary, ultrasound-guided fine needle aspiration:  Positive for metastatic carcinoma; see comment.
T16	PROBLEM 32 45	breast cancer
T17	TREATMENT 62 78	adjuvant therapy
T18	PROBLEM 154 157	HTN
T19	PROBLEM 159 162	HLD
T20	PROBLEM 190 203	stage IIA pT2
T21	PROBLEM 208 222	a L breast IDC
T22	PROBLEM 232 239	grade 2
T23	TEST 241 243	ER
T24	TEST 245 252	PR+/HER
T25	TEST 259 269	FISH ratio
T26	TREATMENT 275 295	high-risk mammaprint
T27	TREATMENT 310 332	bilateral mastectomies
T28	TREATMENT 338 355	left axillary LND
T29	TEST 450 471	a screening mammogram
T30	TEST 528 535	BI-RADS
T31	PROBLEM 574 592	a left breast mass
T32	TEST 609 626	another mammogram
T33	PROBLEM 651 671	several solid masses
T34	PROBLEM 673 702	solid mass in the left breast
T35	PROBLEM 717 748	a solid mass in the left breast
T36	PROBLEM 763 783	prominent lymph node
T37	TEST 806 816	Ultrasound
T38	PROBLEM 843 907	a 11 x 12 x 12 mm irregular, heterogeneous hypoechoic solid mass
T39	PROBLEM 959 1028	a 15 x 12 x 14 mm irregular solid mass in the upper outer left breast
T40	PROBLEM 1075 1096	multiple small masses
T41	TEST 1105 1116	mammography
T42	PROBLEM 1131 1168	two abnormal L axillary lymph nodules
T43	TEST 1171 1211	A 06/20/17 ultrasound-guided core biopsy
T44	PROBLEM 1215 1232	the L breast mass
T45	PROBLEM 1254 1279	invasive ductal carcinoma
T46	PROBLEM 1292 1316	ductal carcinoma in situ
T47	PROBLEM 1318 1368	intermediate nuclear grade, and microcalcification
T48	PROBLEM 1385 1401	ductal carcinoma
T49	PROBLEM 1443 1461	strong PR positive
T50	TEST 1474 1477	HER
T51	TEST 1517 1522	a FNA
T52	TEST 1526 1552	a left axillary lymph node
T53	PROBLEM 1567 1601	metastatic carcinoma of the breast
T54	TREATMENT 1699 1728	bilateral double mastectomies
T55	TREATMENT 1793 1815	bilateral mastectomies
T56	TREATMENT 1817 1852	left axillary lymph node dissection
T57	TREATMENT 1874 1900	bilateral plastics closure
T58	TEST 1903 1916	Her pathology
T59	PROBLEM 1924 1951	IDC multifocal, SBR grade 2
T60	TEST 1983 1990	margins
T61	PROBLEM 2001 2025	Ductal carcinoma in situ
T62	PROBLEM 2055 2094	metastatic carcinoma to two lymph nodes
T63	PROBLEM 2102 2124	1.5 cm largest deposit
T64	PROBLEM 2126 2145	microcalcifications
T65	PROBLEM 2166 2182	ductal carcinoma
T66	PROBLEM 2195 2207	benign ducts
T67	PROBLEM 2269 2287	her surgical sites
T68	TREATMENT 2309 2322	her JP drains
T69	TREATMENT 2369 2390	medical oncology care
T70	TREATMENT 2479 2490	her surgery
T71	PROBLEM 2520 2561	slight more arm stiffness on her left arm
T72	PROBLEM 2588 2648	some associated numbness near her left axilla and left elbow
T73	PROBLEM 2728 2741	breast cancer
T74	PROBLEM 2766 2779	breast cancer
T75	TREATMENT 2784 2801	double mastectomy
T76	PROBLEM 2808 2844	ovarian or pancreatic cancer history
T77	TEST 2908 2923	Genetic testing
T78	PROBLEM 2987 2996	Arthritis
T79	PROBLEM 3002 3029	Breast cancer     left side
T80	PROBLEM 3034 3056	Cataract     right eye
T81	PROBLEM 3061 3099	GERD (gastroesophageal reflux disease)
T82	TREATMENT 3107 3110	PPI
T83	PROBLEM 3115 3137	Glaucoma     both eyes
T84	PROBLEM 3142 3154	Heart murmur
T85	PROBLEM 3160 3174	Hyperlipidemia
T86	PROBLEM 3180 3192	Hypertension
T87	PROBLEM 3198 3215	Migraine headache
T88	PROBLEM 3221 3247	MVP (mitral valve prolapse
T89	PROBLEM 3275 3288	scarlet fever
T90	PROBLEM 3293 3303	Osteopenia
T91	PROBLEM 3309 3313	PONV
T92	PROBLEM 3315 3335	postoperative nausea
T93	PROBLEM 3340 3348	vomiting
T94	TREATMENT 3359 3371	foot surgery
T95	PROBLEM 3396 3413	post op headaches
T96	PROBLEM 3418 3454	Thyroid disease     hyperparathyroid
T97	TREATMENT 3517 3529	APPENDECTOMY
T98	TREATMENT 3540 3552	hysterectomy
T99	TREATMENT 3557 3574	BREAST LUMPECTOMY
T100	PROBLEM 3575 3600	Left     benign pathology
T101	TREATMENT 3605 3651	HAMMER TOE SURGERY      left foot (and bunion)
T102	TREATMENT 3656 3668	HYSTERECTOMY
T103	PROBLEM 3678 3686	fibroids
T104	TREATMENT 3691 3707	LIPOMA RESECTION
T105	TEST 3723 3728	neck-
T106	TREATMENT 3742 3747	Phaco
T107	TREATMENT 3751 3769	IOL      right eye
T108	TREATMENT 3774 3787	TONSILLECTOMY
T109	TREATMENT 3794 3820	vein/clot thermal ablation
T110	TREATMENT 3975 3994	oral contraceptives
T111	TREATMENT 4021 4033	Hysterectomy
T112	PROBLEM 4062 4069	fibroid
T113	PROBLEM 4073 4082	Menopause
T114	TREATMENT 4118 4145	hormone replacement therapy
T115	PROBLEM 4205 4218	breast cancer
T116	PROBLEM 4243 4256	breast cancer
T117	TREATMENT 4261 4278	double mastectomy
T118	PROBLEM 4287 4315	ovarian or pancreatic cancer
T119	PROBLEM 4343 4357	stomach cancer
T120	PROBLEM 4379 4387	leukemia
T121	PROBLEM 4389 4400	lung cancer
T122	PROBLEM 4402 4405	HCC
T123	PROBLEM 4410 4426	laryngeal cancer
T124	TREATMENT 4436 4481	Current Outpatient Prescriptions   Medication
T125	TREATMENT 4506 4529	acetaminophen (TYLENOL)
T126	PROBLEM 4618 4622	Pain
T127	TEST 4626 4630	temp
T128	TREATMENT 4657 4680	acetaminophen (TYLENOL)
T129	PROBLEM 4767 4771	Pain
T130	TREATMENT 4789 4814	ascorbic acid (VITAMIN C)
T131	TREATMENT 4874 4893	atenolol (TENORMIN)
T132	TREATMENT 4949 4973	docusate sodium (COLACE)
T133	TREATMENT 5058 5080	gabapentin (NEURONTIN)
T134	TREATMENT 5175 5199	ibuprofen (ADVIL,MOTRIN)
T135	PROBLEM 5286 5290	Pain
T136	TEST 5294 5298	temp
T137	TREATMENT 5325 5337	multivitamin
T138	TREATMENT 5388 5429	multi vitamin      omeprazole (PRILOSEC)
T139	TREATMENT 5486 5505	simvastatin (ZOCOR)
T140	TREATMENT 5599 5610	medications
T141	PROBLEM 5937 5945	Diabetes
T142	PROBLEM 5958 5971	Breast cancer
T143	PROBLEM 6026 6043	Bleeding disorder
T144	PROBLEM 6056 6060	PONV
T145	PROBLEM 6146 6153	malaise
T146	PROBLEM 6154 6161	fatigue
T147	PROBLEM 6166 6177	weight loss
T148	PROBLEM 6200 6210	congestion
T149	PROBLEM 6215 6225	sinus pain
T150	PROBLEM 6249 6262	double vision
T151	PROBLEM 6292 6297	cough
T152	PROBLEM 6299 6316	sputum production
T153	PROBLEM 6321 6340	shortness of breath
T154	PROBLEM 6374 6384	chest pain
T155	PROBLEM 6386 6398	palpitations
T156	PROBLEM 6403 6415	leg swelling
T157	PROBLEM 6450 6464	abdominal pain
T158	PROBLEM 6466 6478	constipation
T159	PROBLEM 6480 6488	diarrhea
T160	PROBLEM 6493 6502	heartburn
T161	PROBLEM 6536 6545	back pain
T162	PROBLEM 6550 6558	myalgias
T163	PROBLEM 6581 6585	rash
T164	PROBLEM 6594 6623	Post-mastectomy scars healing
T165	PROBLEM 6658 6672	sensory change
T166	PROBLEM 6674 6706	numbness of L axilla and L elbow
T167	PROBLEM 6722 6731	dizziness
T168	PROBLEM 6733 6747	focal weakness
T169	PROBLEM 6749 6757	weakness
T170	PROBLEM 6762 6771	headaches
T171	TEST 6856 6862	Vitals
T172	PROBLEM 6984 6992	distress
T173	PROBLEM 7078 7088	atraumatic
T174	PROBLEM 7140 7161	oropharyngeal exudate
T175	PROBLEM 7255 7270	scleral icterus
T176	TEST 7411 7415	Exam
T177	PROBLEM 7427 7433	gallop
T178	PROBLEM 7441 7453	friction rub
T179	PROBLEM 7461 7467	murmur
T180	TEST 7511 7524	breath sounds
T181	PROBLEM 7536 7556	respiratory distress
T182	PROBLEM 7569 7576	wheezes
T183	PROBLEM 7589 7594	rales
T184	PROBLEM 7656 7666	distension
T185	PROBLEM 7680 7690	tenderness
T186	PROBLEM 7704 7711	rebound
T187	PROBLEM 7719 7727	guarding
T188	PROBLEM 7788 7793	edema
T189	PROBLEM 7797 7807	tenderness
T190	PROBLEM 7811 7820	deformity
T191	PROBLEM 7895 7916	cranial nerve deficit
T192	PROBLEM 7968 7997	healing post-mastectomy scars
T193	PROBLEM 8002 8010	erythema
T194	PROBLEM 8014 8024	fluctuance
T195	PROBLEM 8030 8033	TTP
T196	TEST 8160 8170	Ultrasound
T197	PROBLEM 8231 8253	fibroglandular density
T198	PROBLEM 8362 8393	a 15 mm irregular obscured mass
T199	PROBLEM 8399 8434	associated architectural distortion
T200	PROBLEM 8484 8519	palpable concern in the left breast
T201	PROBLEM 8568 8592	innumerable small masses
T202	PROBLEM 8640 8680	some extension into upper outer quadrant
T203	PROBLEM 8697 8725	associated nipple retraction
T204	TEST 8730 8740	Ultrasound
T205	PROBLEM 8761 8839	a 11 x 12 x 12 mm irregular, not-parallel, heterogeneous hypoechoic solid mass
T206	PROBLEM 8959 8980	the mammographic mass
T207	PROBLEM 8986 9021	associated architectural distortion
T208	PROBLEM 9033 9051	the palpable lumps
T209	PROBLEM 9089 9127	a 15 x 12 x 14 mm irregular solid mass
T210	PROBLEM 9243 9257	calcifications
T211	PROBLEM 9291 9312	multiple small masses
T212	TEST 9321 9332	mammography
T213	PROBLEM 9356 9394	two abnormal left axillary lymph nodes
T214	TEST 9431 9449	coritcal thickness
T215	PROBLEM 9522 9532	malignancy
T216	TEST 9534 9541	BI-RADS
T217	TEST 9577 9587	ultrasound
T218	TEST 9595 9606	core biopsy
T219	PROBLEM 9610 9626	left breast mass
T220	PROBLEM 9683 9708	the two ultrasound masses
T221	TEST 9723 9747	fine needle 
 aspiration
T222	PROBLEM 9751 9784	abnormal left axillary lymph node
T223	TEST 9800 9809	Mammogram
T224	PROBLEM 9870 9892	fibroglandular density
T225	PROBLEM 10001 10032	a 15 mm irregular obscured mass
T226	PROBLEM 10038 10073	associated architectural distortion
T227	PROBLEM 10123 10158	palpable concern in the left breast
T228	PROBLEM 10207 10231	innumerable small masses
T229	PROBLEM 10279 10319	some extension into upper outer quadrant
T230	PROBLEM 10336 10364	associated nipple retraction
T231	TEST 10369 10379	Ultrasound
T232	PROBLEM 10400 10478	a 11 x 12 x 12 mm irregular, not-parallel, heterogeneous hypoechoic solid mass
T233	PROBLEM 10598 10619	the mammographic mass
T234	PROBLEM 10625 10660	associated architectural distortion
T235	PROBLEM 10672 10690	the palpable lumps
T236	PROBLEM 10728 10766	a 15 x 12 x 14 mm irregular solid mass
T237	PROBLEM 10882 10896	calcifications
T238	PROBLEM 10930 10951	multiple small masses
T239	TEST 10960 10971	mammography
T240	PROBLEM 10995 11033	two abnormal left axillary lymph nodes
T241	TEST 11070 11088	coritcal thickness
T242	PROBLEM 11161 11171	malignancy
T243	TEST 11173 11180	BI-RADS
T244	TEST 11214 11224	ultrasound
T245	TEST 11232 11243	core biopsy
T246	PROBLEM 11247 11263	left breast mass
T247	PROBLEM 11320 11345	the two ultrasound masses
T248	TEST 11358 11380	fine needle aspiration
T249	PROBLEM 11384 11417	abnormal left axillary lymph node
T250	TEST 11437 11446	Mammogram
T251	PROBLEM 11470 11499	Solid mass in the left breast
T252	TEST 11529 11558	Ultrasound-guided core biopsy
T253	PROBLEM 11587 11618	2:Solid mass in the left breast
T254	TEST 11648 11677	Ultrasound-guided core biopsy
T255	PROBLEM 11709 11749	:Prominent lymph node in the left axilla
T256	TEST 11766 11795	Ultrasound-guided core biopsy
T257	TEST 11951 11960	Mammogram
T258	PROBLEM 12002 12012	malignancy
T259	TEST 12017 12045	Annual screening mammography
T260	TEST 12060 12091	monthly breast self-examination
T261	TREATMENT 12395 12412	simple mastectomy
T262	PROBLEM 12419 12446	Atypical ductal hyperplasia
T263	PROBLEM 12452 12477	Lobular carcinoma in situ
T264	PROBLEM 12482 12510	atypical lobular hyperplasia
T265	PROBLEM 12516 12525	Papilloma
T266	PROBLEM 12527 12551	usual ductal hyperplasia
T267	PROBLEM 12553 12572	apocrine metaplasia
T268	PROBLEM 12578 12591	duct  ectasia
T269	PROBLEM 12597 12615	Micocalcifications
T270	PROBLEM 12636 12648	benign ducts
T271	TREATMENT 12697 12714	simple mastectomy
T272	PROBLEM 12720 12745	Invasive ductal carcinoma
T273	PROBLEM 12747 12776	multifocal, SBR grade 2 and 1
T274	TEST 12801 12808	margins
T275	PROBLEM 12836 12860	Ductal carcinoma in situ
T276	PROBLEM 12862 12953	intermediate nuclear grade, mixed  cribriform, micropapillary, solid and papillary patterns
T277	PROBLEM 12959 12975	comedo  necrosis
T278	PROBLEM 12999 13008	Papilloma
T279	PROBLEM 13010 13034	usual ductal hyperplasia
T280	PROBLEM 13036 13047	radial scar
T281	PROBLEM 13049 13069	apocrine  metaplasia
T282	PROBLEM 13071 13076	cysts
T283	PROBLEM 13082 13094	duct ectasia
T284	PROBLEM 13100 13139	Metastatic carcinoma to two lymph nodes
T285	PROBLEM 13147 13170	1.5 cm largest  deposit
T286	TEST 13176 13195	Biopsy site changes
T287	PROBLEM 13201 13220	Microcalcifications
T288	PROBLEM 13241 13257	ductal carcinoma
T289	PROBLEM 13271 13283	benign ducts
T290	PROBLEM 13313 13318	tumor
T291	PROBLEM 13370 13380	dissection
T292	PROBLEM 13385 13410	tumor in  ten lymph nodes
T293	TREATMENT 13531 13568	the left mastectomy specimen (part B)
T294	PROBLEM 13570 13581	two lesions
T295	PROBLEM 13609 13625	The first lesion
T296	TEST 13750 13763	a biopsy clip
T297	PROBLEM 13765 13776	This lesion
T298	PROBLEM 13783 13829	a single continuous  invasive ductal carcinoma
T299	PROBLEM 13925 13951	The second lesion  (lesion
T300	PROBLEM 13993 14024	multinodular grossly in  slices
T301	TEST 14048 14080	sequential sampling of lesion #1
T302	PROBLEM 14088 14102	extensive DCIS
T303	PROBLEM 14131 14149	invasive carcinoma
T304	PROBLEM 14300 14304	DCIS
T305	PROBLEM 14313 14321	invasion
T306	PROBLEM 14356 14361	tumor
T307	PROBLEM 14393 14397	DCIS
T308	PROBLEM 14550 14561	SBR grade 2
T309	PROBLEM 14614 14625	SBR grade 1
T310	PROBLEM 14708 14733	Invasive ductal carcinoma
T311	PROBLEM 14821 14831	the lesion
T312	TEST 14907 14917	tumor size
T313	TEST 14928 14945	gross measurement
T314	PROBLEM 14950 14970	Invasive tumor grade
T315	TEST 15007 15016	SBR grade
T316	TEST 15054 15067	Mitotic count
T317	TEST 15072 15079	mitoses
T318	PROBLEM 15119 15152	Glandular/tubular differentiation
T319	TEST 15204 15209	Tumor
T320	TREATMENT 15222 15261	inner central, superior medial to tumor
T321	PROBLEM 15286 15296	tumor size
T322	TEST 15306 15318	the slide B6
T323	PROBLEM 15323 15343	Invasive tumor grade
T324	TEST 15380 15389	SBR grade
T325	TEST 15427 15440	Mitotic count
T326	TEST 15444 15451	mitoses
T327	PROBLEM 15490 15525	Glandular/tubular 
 differentiation
T328	TEST 15660 15670	slides B14
T329	TEST 15672 15675	B22
T330	TEST 15677 15680	B23
T331	TEST 15687 15693	slices
T332	PROBLEM 15707 15717	tumor size
T333	TEST 15743 15758	3 tissue slices
T334	PROBLEM 15763 15783	Invasive tumor grade
T335	TEST 15820 15829	SBR grade
T336	TEST 15867 15880	Mitotic count
T337	TEST 15885 15892	mitoses
T338	PROBLEM 15932 15965	Glandular/tubular differentiation
T339	TEST 16017 16022	Tumor
T340	TREATMENT 16035 16065	central, slide B10, tumor size
T341	TEST 16075 16084	slide B10
T342	PROBLEM 16089 16109	Invasive tumor grade
T343	TEST 16146 16155	SBR grade
T344	TEST 16193 16206	Mitotic count
T345	PROBLEM 16222 16255	Glandular/tubular differentiation
T346	PROBLEM 16361 16388	Lymphatic/vascular invasion
T347	PROBLEM 16508 16522	invasive tumor
T348	PROBLEM 16642 16658	Ductal carcinoma
T349	PROBLEM 16753 16816	Mixed cribriform, micropapillary, solid  and papillary patterns
T350	PROBLEM 16821 16837	Necrosis in DCIS
T351	PROBLEM 16839 16854	Comedo necrosis
T352	PROBLEM 16867 16896	Ductal carcinoma in situ size
T353	PROBLEM 16969 16988	Microcalcifications
T354	PROBLEM 17018 17022	DCIS
T355	PROBLEM 17027 17039	benign ducts
T356	TREATMENT 17044 17061	Resection margins
T357	TEST 17066 17070	DCIS
T358	PROBLEM 17114 17131	Lobular carcinoma
T359	PROBLEM 17157 17178	Non-neoplastic breast
T360	PROBLEM 17180 17189	Papilloma
T361	PROBLEM 17191 17215	usual ductal hyperplasia
T362	PROBLEM 17217 17237	apocrine  metaplasia
T363	PROBLEM 17243 17255	duct ectasia
T364	TEST 17366 17381	micrometastases
T365	TEST 17422 17437	macrometastases
T366	PROBLEM 17457 17483	largest metastasis in node
T367	TEST 17500 17520	Extranodal extension
T368	TEST 17566 17581	Tumor biomarker
T369	TEST 17583 17588	ER/PR
T370	TEST 17611 17636	Immunohistochemical tests
T371	TREATMENT 17641 17676	estrogen and progesterone receptors
T372	TEST 17678 17682	HER2
T373	TEST 17688 17693	Ki-67
T374	TEST 17712 17730	manual morphometry
T375	TEST 17734 17739	block
T376	TEST 17781 17812	The test for estrogen receptors
T377	PROBLEM 17835 17859	strong nuclear  staining
T378	PROBLEM 17871 17882	tumor cells
T379	TREATMENT 17884 17909	Internal positive control
T380	TEST 17972 18007	The test for progesterone receptors
T381	PROBLEM 18030 18054	strong  nuclear staining
T382	PROBLEM 18066 18077	tumor cells
T383	TREATMENT 18079 18104	Internal positive control
T384	TEST 18177 18186	HER2 test
T385	PROBLEM 18188 18202	This carcinoma
T386	PROBLEM 18220 18253	HER2 oncoprotein  over-expression
T387	PROBLEM 18281 18295	this carcinoma
T388	TEST 18325 18350	Ki-67 proliferation index
T389	TEST 18378 18382	HER2
T390	PROBLEM 18467 18478	Tumor cells
T391	TEST 18567 18578	tumor cells
T392	TEST 18593 18610	Mean HER2 signals
T393	TEST 18611 18618	nucleus
T394	TEST 18625 18651	Mean Centromere 17 signals
T395	TEST 18652 18659	nucleus
T396	TEST 18671 18676	Ratio
T397	TEST 18680 18684	HER2
T398	TEST 18686 18692	Cent17
T399	TEST 18701 18705	ISCN
T400	TEST 18708 18715	nuc ish
T401	TEST 18729 18732	CEP
T402	TEST 18838 18880	Left breast, ultrasound-guided core biopsy
T403	PROBLEM 18887 18912	Invasive ductal carcinoma
T404	PROBLEM 18931 18955	Ductal carcinoma in situ
T405	PROBLEM 18957 19004	intermediate nuclear grade, cribriform  pattern
T406	PROBLEM 19010 19031	focal comedo necrosis
T407	PROBLEM 19038 19056	Microcalcification
T408	PROBLEM 19073 19089	ductal carcinoma
T409	TEST 19113 19138	Breast Needle Core Biopsy
T410	PROBLEM 19188 19213	Invasive ductal carcinoma
T411	PROBLEM 19218 19237	Invasive tumor size
T412	PROBLEM 19282 19287	tumor
T413	PROBLEM 19321 19341	Invasive tumor grade
T414	TEST 19405 19422	excision specimen
T415	TEST 19460 19473	Mitotic count
T416	PROBLEM 19503 19536	Glandular/tubular differentiation
T417	TEST 19553 19571	Total points/grade
T418	PROBLEM 19583 19590	grade 2
T419	PROBLEM 19595 19618	Lymphovascular invasion
T420	PROBLEM 19639 19663	Ductal carcinoma in situ
T421	PROBLEM 19698 19714	comedo  necrosis
T422	PROBLEM 19720 19736	Ductal carcinoma
T423	PROBLEM 19777 19796	Microcalcifications
T424	PROBLEM 19823 19827	DCIS
T425	PROBLEM 19832 19849	Lobular carcinoma
T426	TEST 19875 19906	The test for estrogen receptors
T427	PROBLEM 19929 19953	strong nuclear  staining
T428	PROBLEM 19965 19976	tumor cells
T429	TREATMENT 19978 20003	Internal positive control
T430	TEST 20066 20101	The test for progesterone receptors
T431	PROBLEM 20124 20160	moderate to  strong nuclear staining
T432	PROBLEM 20172 20183	tumor cells
T433	TREATMENT 20185 20211	Internal positive  control
T434	TEST 20283 20292	HER2 test
T435	PROBLEM 20294 20308	This carcinoma
T436	PROBLEM 20325 20358	HER2 oncoprotein  over-expression
T437	PROBLEM 20386 20400	this carcinoma
T438	TEST 20430 20455	Ki-67 proliferation index
T439	TEST 20478 20481	FNA
T440	PROBLEM 20519 20543	Left axillary lymph node
T441	PROBLEM 20545 20567	fine needle aspiration
T442	TEST 20629 20669	ultrasound-guided fine needle aspiration
T443	PROBLEM 20685 20705	metastatic carcinoma
T444	TEST 20736 20749	The aspirates
T445	PROBLEM 20785 20831	scattered irregular  sheets of malignant cells
T446	PROBLEM 20884 20899	enlarged nuclei
T447	PROBLEM 20905 20931	irregular nuclear contours
T448	PROBLEM 20936 20964	scant to  moderate cytoplasm
T449	TEST 20966 20987	The cell block sample
T450	PROBLEM 21037 21071	metastatic carcinoma of the breast
T451	TEST 21082 21124	the  corresponding left breast core biopsy
T452	PROBLEM 21210 21213	HTN
T453	PROBLEM 21215 21218	HLD
T454	PROBLEM 21248 21261	stage IIA pT2
T455	PROBLEM 21266 21280	a L breast IDC
T456	PROBLEM 21290 21297	grade 2
T457	TEST 21299 21301	ER
T458	TEST 21303 21310	PR+/HER
T459	TEST 21317 21327	FISH ratio
T460	TREATMENT 21333 21353	high-risk mammaprint
T461	TREATMENT 21368 21390	bilateral mastectomies
T462	TREATMENT 21396 21413	left axillary LND
T463	PROBLEM 21481 21494	stage IIA IDC
T464	PROBLEM 21500 21528	known lymph node involvement
T465	TREATMENT 21572 21594	bilateral mastectomies
T466	PROBLEM 21603 21632	her early stage breast cancer
T467	PROBLEM 21638 21661	positive LN involvement
T468	TREATMENT 21663 21677	the mammaprint
T469	TREATMENT 21735 21749	Her Mammaprint
T470	TREATMENT 21813 21825	chemotherapy
T471	TREATMENT 21852 21874	an aromatase inhibitor
T472	TREATMENT 21940 21952	chemotherapy
T473	TREATMENT 21987 21996	treatment
T474	TREATMENT 22002 22004	AC
T475	TREATMENT 22010 22020	paclitaxel
T476	TREATMENT 22066 22078	chemotherapy
T477	PROBLEM 22090 22097	fatigue
T478	PROBLEM 22099 22102	n/v
T479	PROBLEM 22108 22117	hair loss
T480	TREATMENT 22164 22173	treatment
T481	TREATMENT 22272 22284	chemotherapy
T482	TEST 22299 22313	a baseline TTE
T483	TREATMENT 22362 22378	an anthracycline
T484	TREATMENT 22380 22389	IV access
T485	TREATMENT 22403 22409	a PAC)
T486	TREATMENT 22415 22436	chemotherapy teaching
T487	PROBLEM 22481 22494	breast cancer
T488	PROBLEM 22584 22597	BRCA positive
T489	TEST 22674 22689	genetic testing
T490	TREATMENT 22727 22739	chemotherapy
T491	TREATMENT 22745 22760	AC + paclitaxel
T492	TEST 22826 22829	TTE
T493	TREATMENT 22843 22868	pre-chemotherapy teaching
T494	TREATMENT 22872 22886	port placement
T495	ClinicalCondition 32 45	breast cancer
T496	Age 128 130	70
T497	ClinicalCondition 154 157	HTN
A1	ChronicVal T497 chronic
T498	ClinicalCondition 159 162	HLD
A2	ChronicVal T498 chronic
T499	Histology 219 222	IDC
A3	HistoryVal T499 new
A4	EpisodeDescription T499 FirstOccurrence
T500	Laterality 210 211	L
T501	Site 212 218	breast
R1	LateralityOfSite Arg1:T500 Arg2:T501	
R2	SiteOf Arg1:T501 Arg2:T499	
T502	TNM 200 209	pT2(m)N1a
A5	HistoryVal T502 new
A6	EpisodeDescription T502 FirstOccurrence
T503	Stage 196 199	IIA
A7	HistoryVal T503 new
A8	EpisodeDescription T503 FirstOccurrence
T504	Size 224 230	3.9 cm
T505	Grade 238 239	2
T506	BiomarkerName 241 243	ER
A9	HistoryVal T506 new
A10	EpisodeDescription T506 FirstOccurrence
T507	BiomarkerName 245 247	PR
A11	HistoryVal T507 new
A12	EpisodeDescription T507 FirstOccurrence
T508	BiomarkerName 249 252	HER
A13	HistoryVal T508 new
A14	EpisodeDescription T508 FirstOccurrence
T509	BiomarkerResult 243 244	+
A15	HistoryVal T509 new
A16	EpisodeDescription T509 FirstOccurrence
A17	BiomarkerResultVal T509 Positive
T510	BiomarkerResult 247 248	+
A18	HistoryVal T510 new
A19	EpisodeDescription T510 FirstOccurrence
A20	BiomarkerResultVal T510 Positive
T511	BiomarkerResult 252 253	-
A21	HistoryVal T511 new
A22	EpisodeDescription T511 FirstOccurrence
A23	BiomarkerResultVal T511 Negative
T512	Pathology 259 263	FISH
A24	IntentVal T512 diagnosis
T513	RadPathResult 270 273	1.1
R3	ResultOfTest Desc:T513 Test:T512	
R4	BiomarkerRel Arg1:T509 Arg2:T506	
R5	BiomarkerRel Arg1:T510 Arg2:T507	
R6	BiomarkerRel Arg1:T511 Arg2:T508	
T514	GenomicTest 285 295	mammaprint
A25	IntentVal T514 others
A26	GenomicTestType T514 GeneExpression
T515	GenomicTestResult 275 284	high-risk
A27	GenomicTestType T515 GeneExpression
R7	ResultOfTest Desc:T515 Test:T514	
T516	Datetime 301 309	08/18/17
T517	ProcedureName 320 332	mastectomies
A28	IntentVal T517 treatment-curative
A29	TreatmentTypeVal T517 local
A30	TreatmentCategory T517 Others
T518	Site 310 319	bilateral
R8	SiteOf Arg1:T518 Arg2:T517	
T519	ProcedureName 352 355	LND
A31	IntentVal T519 staging
A32	TreatmentTypeVal T519 local
A33	TreatmentCategory T519 Others
T520	Site 343 351	axillary
T521	Laterality 338 342	left
R9	LateralityOfSite Arg1:T521 Arg2:T520	
R10	SiteOf Arg1:T520 Arg2:T519	
R11	HappensAtOnDuring Arg1:T517 Arg2:T516	
R12	HappensAtOnDuring Arg1:T519 Arg2:T516	
T522	LymphNodeInvolvement 361 369	2/12 LN+
A34	HistoryVal T522 new
A35	EpisodeDescription T522 FirstOccurrence
R13	TestOrProcedureReveals Test:T519 Desc:T522	
T523	Radiology 462 471	mammogram
A36	IntentVal T523 screening
T524	Datetime 482 490	01/25/17
R14	HappensAtOnDuring Arg1:T523 Arg2:T524	
T525	RadPathResult 528 537	BI-RADS 1
A37	RadPathResultVal T525 NoDisease
R15	ResultOfTest Desc:T525 Test:T523	
T526	Symptom 588 592	mass
A38	IsPresentOnFirstCancerDiagnosis T526 yes
A39	IsCausedByDiagnosedCancer T526 yes
T527	Site 581 587	breast
T528	Laterality 576 580	left
R16	LateralityOfSite Arg1:T528 Arg2:T527	
R17	SiteOf Arg1:T527 Arg2:T526	
T529	Duration 540 554	Several months
R18	HappensAfter Arg1:T526 Arg2:T529	
T530	Radiology 617 626	mammogram
A40	IntentVal T530 diagnosis
T531	Datetime 630 638	05/27/17
R19	HappensAtOnDuring Arg1:T530 Arg2:T531	
T532	RadPathResult 673 683	solid mass
A41	RadPathResultVal T532 InitialCancerDiagnosis
T533	Site 696 702;706 715	breast 3 o'clock
T534	Laterality 691 695	left
T535	RadPathResult 719 729	solid mass
A42	RadPathResultVal T535 InitialCancerDiagnosis
T536	Site 742 748;752 762	breast 1 o'clock;
T537	Laterality 737 741	left
R20	LateralityOfSite Arg1:T534 Arg2:T533	
R21	SiteOf Arg1:T533 Arg2:T532	
R22	LateralityOfSite Arg1:T537 Arg2:T536	
R23	SiteOf Arg1:T536 Arg2:T535	
R24	ResultOfTest Desc:T532 Test:T530	
R25	ResultOfTest Desc:T535 Test:T530	
T538	RadPathResult 763 783	prominent lymph node
A43	RadPathResultVal T538 InitialCancerDiagnosis
T539	Site 796 802	axilla
T540	Laterality 791 795	left
R26	LateralityOfSite Arg1:T540 Arg2:T539	
R27	SiteOf Arg1:T539 Arg2:T538	
R28	ResultOfTest Desc:T538 Test:T530	
T541	Radiology 806 816	Ultrasound
A44	IntentVal T541 diagnosis
T542	RadPathResult 845 907	11 x 12 x 12 mm irregular, heterogeneous hypoechoic solid mass
A45	RadPathResultVal T542 InitialCancerDiagnosis
T543	Site 915 928;934 940;945 954	outer central breast 3 o'clock
T544	Laterality 929 933	left
R29	LateralityOfSite Arg1:T544 Arg2:T543	
R30	SiteOf Arg1:T543 Arg2:T542	
R31	ResultOfTest Desc:T542 Test:T541	
T545	RadPathResult 961 997	15 x 12 x 14 mm irregular solid mass
A46	RadPathResultVal T545 InitialCancerDiagnosis
T546	Site 1005 1016;1022 1028;1033 1042	upper outer breast 2 o'clock
T547	Laterality 1017 1021	left
R32	LateralityOfSite Arg1:T547 Arg2:T546	
R33	SiteOf Arg1:T546 Arg2:T545	
R34	ResultOfTest Desc:T545 Test:T541	
T548	RadPathResult 1131 1168	two abnormal L axillary lymph nodules
A47	RadPathResultVal T548 InitialCancerDiagnosis
R35	ResultOfTest Desc:T548 Test:T541	
T549	Datetime 1173 1181	06/20/17
T550	Pathology 1182 1211	ultrasound-guided core biopsy
A48	IntentVal T550 diagnosis
T551	Site 1221 1246	breast mass at  3 o'clock
T552	Laterality 1219 1220	L
R36	LateralityOfSite Arg1:T552 Arg2:T551	
R37	SiteOf Arg1:T551 Arg2:T550	
R38	HappensAtOnDuring Arg1:T550 Arg2:T549	
T553	Histology 1254 1279	invasive ductal carcinoma
A49	HistoryVal T553 new
A50	EpisodeDescription T553 FirstOccurrence
T554	Histology 1292 1316	ductal carcinoma in situ
A51	HistoryVal T554 new
A52	EpisodeDescription T554 FirstOccurrence
R39	TestOrProcedureReveals Test:T550 Desc:T553	
R40	TestOrProcedureReveals Test:T550 Desc:T554	
T555	BiomarkerName 1423 1425	ER
A53	HistoryVal T555 new
A54	EpisodeDescription T555 FirstOccurrence
T556	BiomarkerResult 1426 1441	positive (100%)
A55	HistoryVal T556 new
A56	EpisodeDescription T556 FirstOccurrence
A57	BiomarkerResultVal T556 Positive
T557	BiomarkerName 1450 1452	PR
A58	HistoryVal T557 new
A59	EpisodeDescription T557 FirstOccurrence
T558	BiomarkerResult 1453 1468	positive (>95%)
A60	HistoryVal T558 new
A61	EpisodeDescription T558 FirstOccurrence
A62	BiomarkerResultVal T558 Positive
T559	BiomarkerName 1474 1479	HER-2
A63	HistoryVal T559 new
A64	EpisodeDescription T559 FirstOccurrence
T560	BiomarkerResult 1480 1488	negative
A65	HistoryVal T560 new
A66	EpisodeDescription T560 FirstOccurrence
A67	BiomarkerResultVal T560 Negative
R41	BiomarkerRel Arg1:T560 Arg2:T559	
R42	BiomarkerRel Arg1:T558 Arg2:T557	
R43	BiomarkerRel Arg1:T556 Arg2:T555	
R44	TestOrProcedureReveals Test:T550 Desc:T555	
R45	TestOrProcedureReveals Test:T550 Desc:T557	
R46	TestOrProcedureReveals Test:T550 Desc:T559	
T561	Pathology 1519 1522	FNA
A68	IntentVal T561 diagnosis
T562	Site 1533 1552	axillary lymph node
T563	Laterality 1528 1532	left
R47	LateralityOfSite Arg1:T563 Arg2:T562	
R48	SiteOf Arg1:T562 Arg2:T561	
T564	Metastasis 1567 1577	metastatic
A69	HistoryVal T564 new
A70	EpisodeDescription T564 FirstOccurrence
R49	TestOrProcedureReveals Test:T561 Desc:T564	
T565	ProcedureName 1716 1728	mastectomies
A71	IntentVal T565 treatment-curative
A72	TreatmentTypeVal T565 local
A73	TreatmentCategory T565 Others
T566	Site 1699 1708	bilateral
R50	SiteOf Arg1:T566 Arg2:T565	
T567	ProcedureName 1803 1815	mastectomies
A74	IntentVal T567 treatment-curative
A75	TreatmentTypeVal T567 local
A76	TreatmentCategory T567 Others
T568	Site 1793 1802	bilateral
R51	SiteOf Arg1:T568 Arg2:T567	
T569	ProcedureName 1831 1852	lymph node dissection
A77	IntentVal T569 staging
A78	TreatmentTypeVal T569 local
A79	TreatmentCategory T569 Others
T570	Site 1822 1830	axillary
T571	Laterality 1817 1821	left
R52	LateralityOfSite Arg1:T571 Arg2:T570	
R53	SiteOf Arg1:T570 Arg2:T569	
T572	ProcedureName 1884 1900	plastics closure
T573	Site 1874 1883	bilateral
R54	SiteOf Arg1:T573 Arg2:T572	
T575	Histology 1924 1927	IDC
T576	Size 1975 1981	3.9 cm
A81	HistoryVal T576 new
A82	EpisodeDescription T576 FirstOccurrence
T577	MarginStatus 1991 1999	negative
A83	MarginVal T577 MoreThan2mm(Neg)
T578	Histology 2001 2025	Ductal carcinoma in situ
A84	HistoryVal T578 new
A85	EpisodeDescription T578 FirstOccurrence
T574	Metastasis 2055 2065	metastatic
A80	HistoryVal T574 new
A86	EpisodeDescription T574 FirstOccurrence
T579	LymphNodeInvolvement 2079 2094	two lymph nodes
A87	HistoryVal T579 new
A88	EpisodeDescription T579 FirstOccurrence
R55	TestOrProcedureReveals Test:T567 Desc:T575	
R56	TestOrProcedureReveals Test:T567 Desc:T576	
R57	ProcedureDesc Procedure:T567 Desc:T577	
R58	TestOrProcedureReveals Test:T567 Desc:T578	
R59	TestOrProcedureReveals Test:T567 Desc:T574	
R60	TestOrProcedureReveals Test:T567 Desc:T579	
T580	Datetime 2436 2446	10/10/2017
T581	Datetime 2254 2262	08/31/17
T582	Symptom 2536 2545	stiffness
T583	Site 2558 2561	arm
T584	Laterality 2553 2557	left
R61	LateralityOfSite Arg1:T584 Arg2:T583	
R62	SiteOf Arg1:T583 Arg2:T582	
T585	Symptom 2604 2612	numbness
T586	Site 2627 2633	axilla
T587	Site 2643 2648	elbow
T588	Laterality 2622 2626	left
T589	Laterality 2638 2642	left
R63	LateralityOfSite Arg1:T589 Arg2:T587	
R64	LateralityOfSite Arg1:T588 Arg2:T586	
R65	SiteOf Arg1:T586 Arg2:T585	
R66	SiteOf Arg1:T587 Arg2:T585	
T590	ClinicalCondition 2766 2779	breast cancer
A89	ExperiencerVal T590 family
T591	ProcedureName 2784 2801	double mastectomy
A90	IntentVal T591 treatment-curative
A91	TreatmentTypeVal T591 local
A92	TreatmentCategory T591 Others
R67	TestOrProcedureConductedForProblem Test:T591 Prob:T590	
T592	ClinicalCondition 2728 2741	breast cancer
T593	Age 2749 2752	60s
A93	ExperiencerVal T592 family
R68	HappensAtOnDuring Arg1:T592 Arg2:T593	
T594	GenomicTest 2908 2923	Genetic testing
A94	NegationModalityVal T594 negated
T595	ClinicalCondition 2987 2996	Arthritis
A95	ChronicVal T595 chronic
T596	ClinicalCondition 3002 3015	Breast cancer
T597	ClinicalCondition 3034 3042	Cataract
T598	Site 3020 3024	left
T599	Site 3047 3052	right
T600	ClinicalCondition 3061 3065	GERD
T601	MedicationName 3107 3110	PPI
R69	TreatmentAdministeredForProblem Treatment:T601 Prob:T600	
R70	SiteOf Arg1:T599 Arg2:T597	
T602	ClinicalCondition 3115 3123	Glaucoma
T603	Site 3128 3137	both eyes
R71	SiteOf Arg1:T603 Arg2:T602	
T604	ClinicalCondition 3160 3174	Hyperlipidemia
T605	ClinicalCondition 3180 3192	Hypertension
A96	ChronicVal T605 chronic
T606	ClinicalCondition 3198 3206	Migraine
T607	ClinicalCondition 3142 3154	Heart murmur
A97	ChronicVal T604 chronic
A98	ChronicVal T606 chronic
T608	ClinicalCondition 3226 3247	mitral valve prolapse
T609	ClinicalCondition 3275 3288	scarlet fever
A99	ContinuityVal T609 stopped
T610	ClinicalCondition 3293 3303	Osteopenia
T611	ClinicalCondition 3315 3348	postoperative nausea and vomiting
T612	ClinicalCondition 3438 3454	hyperparathyroid
T613	ProcedureName 3517 3529	APPENDECTOMY
T614	ProcedureName 3540 3552	hysterectomy
T615	ProcedureName 3564 3574	LUMPECTOMY
A100	IntentVal T615 treatment-curative
A101	TreatmentTypeVal T615 local
A102	TreatmentCategory T615 Others
T616	Site 3557 3563	BREAST
T617	Laterality 3575 3579	Left
R72	LateralityOfSite Arg1:T617 Arg2:T616	
R73	SiteOf Arg1:T616 Arg2:T615	
T618	ProcedureName 3605 3623	HAMMER TOE SURGERY
T619	Laterality 3629 3633	left
T620	Site 3634 3638	foot
R74	LateralityOfSite Arg1:T619 Arg2:T620	
R75	SiteOf Arg1:T620 Arg2:T618	
T621	ProcedureName 3656 3668	HYSTERECTOMY
T622	ClinicalCondition 3678 3686	fibroids
R76	TestOrProcedureConductedForProblem Test:T621 Prob:T622	
T623	ProcedureName 3691 3707	LIPOMA RESECTION
T624	Site 3723 3727	neck
T625	Laterality 3713 3717	left
R77	LateralityOfSite Arg1:T625 Arg2:T624	
R78	SiteOf Arg1:T624 Arg2:T623	
T626	ProcedureName 3742 3754	Phaco w/ IOL
T627	Site 3766 3769	eye
T628	Laterality 3760 3765	right
R79	LateralityOfSite Arg1:T628 Arg2:T627	
R80	SiteOf Arg1:T627 Arg2:T626	
T629	ProcedureName 3774 3787	TONSILLECTOMY
T630	ProcedureName 3794 3820	vein/clot thermal ablation
T631	Site 3832 3835	leg
T632	Laterality 3826 3831	right
R81	LateralityOfSite Arg1:T632 Arg2:T631	
R82	SiteOf Arg1:T631 Arg2:T630	
T633	PatientCharacteristics 3866 3874	Menarche
T634	Age 3886 3888	13
R83	BeginsOnOrAt Arg1:T633 Arg2:T634	
T635	Age 3958 3960	29
T636	PatientCharacteristics 3925 3950	first full term pregnancy
R84	HappensAtOnDuring Arg1:T636 Arg2:T635	
T637	PatientCharacteristics 3903 3919	gravida 1 para 1
T638	TreatmentType 3975 3994	oral contraceptives
T639	Duration 3999 4007	6 months
T640	Age 4015 4017	23
R85	HappensOverlapping Arg1:T638 Arg2:T639	
R86	HappensAtOnDuring Arg1:T638 Arg2:T640	
T641	ProcedureName 4021 4033	Hysterectomy
T642	Age 4051 4053	29
T643	ClinicalCondition 4062 4069	fibroid
R87	HappensAtOnDuring Arg1:T641 Arg2:T642	
R88	TestOrProcedureConductedForProblem Test:T641 Prob:T643	
T644	ClinicalCondition 4073 4082	Menopause
A103	ChronicVal T644 chronic
T645	Age 4094 4096	50
R89	BeginsOnOrAt Arg1:T644 Arg2:T645	
T646	TreatmentType 4118 4146	hormone replacement therapy.
A104	NegationModalityVal T646 negated
T647	ClinicalCondition 4205 4218	breast cancer
A105	ExperiencerVal T647 family
T648	Age 4226 4229	60s
R90	HappensAtOnDuring Arg1:T647 Arg2:T648	
T649	ClinicalCondition 4243 4256	breast cancer
A106	ExperiencerVal T649 family
T650	ProcedureName 4261 4278	double mastectomy
A107	IntentVal T650 treatment-curative
A108	TreatmentTypeVal T650 local
A109	TreatmentCategory T650 Others
R91	TestOrProcedureConductedForProblem Test:T650 Prob:T649	
T651	ClinicalCondition 4343 4357	stomach cancer
A110	ExperiencerVal T651 family
A111	SectionSkipType T5 medications
T652	LivingCondition 5656 5691	lives in ***** ***** in ***** *****
T653	LivingCondition 5715 5766	living in ***** with her daughter and grandchildren
T654	Employment 5781 5808	elementary school counselor
T655	Tobacco 5818 5824	smoker
A112	IsStoppedOrContinuing T655 stopped
T656	Duration 5850 5858	10 years
T657	Datetime 5865 5876	decades ago
R92	HappensAtOnDuring Arg1:T655 Arg2:T656	
R93	EndsOnOrAt Arg1:T655 Arg2:T657	
T658	ClinicalCondition 5937 5945	Diabetes
A113	ChronicVal T658 chronic
A114	ExperiencerVal T658 family
T659	ClinicalCondition 5958 5971	Breast cancer
A115	ExperiencerVal T659 family
T660	Symptom 6674 6682	numbness
T661	Site 6688 6694	axilla
T662	Site 6701 6706	elbow
T663	Laterality 6686 6687	L
T664	Laterality 6699 6700	L
R94	LateralityOfSite Arg1:T663 Arg2:T661	
R95	LateralityOfSite Arg1:T664 Arg2:T662	
R96	SiteOf Arg1:T661 Arg2:T660	
R97	SiteOf Arg1:T662 Arg2:T660	
T8	SectionSkip 6816 7794;7797 8129	Physical Examination:   Physical Exam   Vitals reviewed.  Constitutional: She is oriented to person, place, and time. She appears well-developed and well-nourished. No distress.   Older woman, non-toxic, accompanied by daughter   HENT:   Head: Normocephalic and atraumatic.   Mouth/Throat: Oropharynx is clear and moist. No oropharyngeal exudate.   Eyes: EOM are normal. Right eye exhibits no discharge. Left eye exhibits no discharge. No scleral icterus.   Neck: Normal range of motion. Neck supple.   Cardiovascular: Normal rate, regular rhythm, normal heart sounds and intact distal pulses.  Exam reveals no gallop and no friction rub.    No murmur heard.  Pulmonary/Chest: Effort normal and breath sounds normal. No respiratory distress. She has no wheezes. She has no rales.   Abdominal: Soft. Bowel sounds are normal. She exhibits no distension. There is no tenderness. There is no rebound and no guarding.   Musculoskeletal: Normal range of motion. She exhibits no edema, tenderness or deformity.   Neurological: She is alert and oriented to person, place, and time. No cranial nerve deficit. Coordination normal.   Skin: Skin is warm.   Well-healing post-mastectomy scars, no erythema or fluctuance, not TTP   Psychiatric: She has a normal mood and affect. Her behavior is normal. Thought content normal
A116	SectionSkipType T8 physical_exam
T665	Datetime 8151 8159	06/20/17
T666	Radiology 8160 8170	Ultrasound
A117	IntentVal T666 diagnosis
R98	HappensAtOnDuring Arg1:T666 Arg2:T665	
T667	RadPathResult 9534 9543	BI-RADS 5
A120	RadPathResultVal T667 InitialCancerDiagnosis
R99	ResultOfTest Desc:T667 Test:T666	
T668	Site 9493 9499	breast
T669	Laterality 9488 9492	Left
R100	LateralityOfSite Arg1:T669 Arg2:T668	
R101	SiteOf Arg1:T668 Arg2:T667	
T670	SectionSkip 10380 11109	Findings:  There is a 11 x 12 x 12 mm irregular, not-parallel, heterogeneous hypoechoic solid mass with angular margins, in the outer central left breast, at approximately 3 o'clock, 8 cm from nipple, corresponding to the mammographic mass with associated architectural distortion and one of the palpable lumps. Vascularity is present.    There is a 15 x 12 x 14 mm irregular solid mass with angular margins, in the upper outer left breast, at approximately 2 o'clock, 3 cm from nipple, which contains calcifications, likely within the large area of multiple small masses seen at mammography.    There are at least two abnormal left axillary lymph nodes at 2:00, 20cm from the nipple, with coritcal thickness measuring up to 9mm.
A121	SectionSkipType T670 radiology_report
T13	SectionSkip 12339 13585;13588 15507;15510 17392;17395 17526	08/18/2017 FINAL PATHOLOGIC DIAGNOSIS  A. Right breast, simple mastectomy:   1. Atypical ductal hyperplasia.  2. Lobular carcinoma in situ and atypical lobular hyperplasia.  3. Papilloma, usual ductal hyperplasia, apocrine metaplasia, and duct  ectasia.  4. Micocalcifications in association with benign ducts.  5. Benign skin and nipple.    B. Left breast, simple mastectomy:  1. Invasive ductal carcinoma, multifocal, SBR grade 2 and 1, largest  focus 3.9 cm, margins negative; see comment.  2. Ductal carcinoma in situ, intermediate nuclear grade, mixed  cribriform, micropapillary, solid and papillary patterns with comedo  necrosis, margins negative.  3. Papilloma, usual ductal hyperplasia, radial scar, apocrine  metaplasia, cysts, and duct ectasia.  4. Metastatic carcinoma to two lymph nodes (2/2), 1.5 cm largest  deposit.  5. Biopsy site changes.  6. Microcalcifications in association with ductal carcinoma in situ and  benign ducts.  7. Skin and nipple with no tumor.    C. Left axillary level 1 and level 2 contents, dissection: No tumor in  ten lymph nodes (0/10).    D. Left breast skin, excision: Benign skin.    E. Right breast skin, excision: Benign skin.    COMMENT:  For the left mastectomy specimen (part B), two lesions are identified  grossly. The first lesion (designated as lesion #1 in the gross  description) is in the lower central breast, measures 3.0 cm and is  associated with a biopsy clip. This lesion shows a single continuous  invasive ductal carcinoma microscopically, spans slices 9 to 11 and  measures 3.0 cm (tumor #1 in the synoptic comment). The second lesion  (lesion #2) is superior to lesion #1 and appears multinodular grossly in  slices 7 to 11. Extensive and sequential sampling of lesion #1 shows  extensive DCIS with three separate foci of invasive carcinoma:  designated as tumors #2 to 4 as in the synoptic comment. Tumor #2 is in  slice 7 and tumor #3 in slices 9 to 11, separated by slice 8, which  shows DCIS without invasion (slides B7 and B26). Tumor #1 and tumor #3  are separated by 1.8 cm of DCIS as in slide B9. Tumor #4 is in ***** 9  and is 0.8 cm away from tumor #3 as in slide B10.     Tumors #1 to 3 have overall similar morphology and are of SBR grade 2,  while tumor #4 has different morphology and is of SBR grade 1.     Breast Tumor Synoptic Comment   - Laterality: Left.   - Invasive tumor type: Invasive ductal carcinoma, four foci, summarized  as follows:  Tumor #1: 3.0 cm (lower central, corresponding to the lesion that was  biopsied in *****-*****. Slides B8, B21 and B24. Slices June 13, tumor size  based on gross measurement)  - Invasive tumor grade (modified Scarff-Bloom-Richardson): SBR grade 2    - Nuclear grade: 2 points.    - Mitotic count: 12 mitoses / 10 high power fields, 2 points.    - Glandular/tubular differentiation: 3 points.    - Total points: 7 points = grade 2.  Tumor #2: 0.9 cm (inner central, superior medial to tumor #1, slide B6,  slice 7, tumor size based on the slide B6)  - Invasive tumor grade (modified Scarff-Bloom-Richardson): SBR grade 2    - Nuclear grade: 2 points.    - Mitotic count: 2 mitoses / 10 high power fields, 1 point.    - Glandular/tubular differentiation: 3 points.    - Total points: 6 points = grade 2.  Tumor #3: 3.9 cm (central to outer, superior to tumor #1 and lateral to  tumor #2, slides B14, B22, B23, B25, slices ***** *****, tumor size based on  involvement of 3 tissue slices)  - Invasive tumor grade (modified Scarff-Bloom-Richardson): SBR grade 2    - Nuclear grade: 2 points.    - Mitotic count: 14 mitoses / 10 high power fields, 2 points.    - Glandular/tubular differentiation: 3 points.    - Total points: 7 points = grade 2.  Tumor #4: 0.2 cm (central, slide B10, tumor size based on slide B10)  - Invasive tumor grade (modified Scarff-Bloom-Richardson): SBR grade 1    - Nuclear grade: 2 points.    - Mitotic count: 1 point.    - Glandular/tubular differentiation: 1 point.    - Total points: 4 points = grade 2.    - EIC (extensive intraductal component): Present.  - Lymphatic/vascular invasion: Not identified.  - Skin/nipple: Not involved by tumor.  - Skeletal muscle: No skeletal muscle present.  - Margins for invasive tumor: Negative: 0.6 cm to the closest anterior  inferior margin (slide B24) and > 1 cm away from all other margins.       - Ductal carcinoma in situ (DCIS): Present.  - DCIS nuclear grade: Intermediate.  - DCIS architectural patterns: Mixed cribriform, micropapillary, solid  and papillary patterns.  - Necrosis in DCIS: Comedo necrosis present.  - Ductal carcinoma in situ size: Present in 6 contiguous slices (slices  7 to 12), spanning 7.8 cm.   - Microcalcifications: Present in association with DCIS and benign ducts.  - Resection margins for DCIS: Negative, >1 cm away from all margins.  - Lobular carcinoma in situ: Not present.  - Non-neoplastic breast: Papilloma, usual ductal hyperplasia, apocrine  metaplasia, and duct ectasia.  - Lymph node status: Positive:      - Total number of nodes examined: 12.      - Total number of nodes with micrometastases: 0.      - Total number of nodes with macrometastases: 2.      - Size of largest metastasis in node: 1.5 cm.      - Extranodal extension: None
A123	SectionSkipType T13 pathology_report
T672	TNM 17550 17559	pT2(m)N1a
A124	HistoryVal T672 new
A125	EpisodeDescription T672 FirstOccurrence
T673	BiomarkerName 17794 17812	estrogen receptors
A126	HistoryVal T673 new
A127	EpisodeDescription T673 FirstOccurrence
T674	BiomarkerResult 17816 17824	positive
A128	HistoryVal T674 new
A129	EpisodeDescription T674 FirstOccurrence
A130	BiomarkerResultVal T674 Positive
R102	BiomarkerRel Arg1:T673 Arg2:T674	
T675	BiomarkerName 17985 18007	progesterone receptors
A131	HistoryVal T675 new
A132	EpisodeDescription T675 FirstOccurrence
T676	BiomarkerResult 18011 18019	positive
A133	HistoryVal T676 new
A134	EpisodeDescription T676 FirstOccurrence
A135	BiomarkerResultVal T676 Positive
R103	BiomarkerRel Arg1:T675 Arg2:T676	
T677	BiomarkerName 18220 18224	HER2
A136	HistoryVal T677 new
A137	EpisodeDescription T677 FirstOccurrence
T678	BiomarkerResult 18206 18215	equivocal
A138	HistoryVal T678 new
A139	EpisodeDescription T678 FirstOccurrence
A140	BiomarkerResultVal T678 Unclear
R104	BiomarkerRel Arg1:T678 Arg2:T677	
T679	Pathology 18325 18330	Ki-67
T680	RadPathResult 18352 18361	20 to 30%
R105	ResultOfTest Desc:T680 Test:T679	
T681	Datetime 18367 18377	08/18/2017
T682	Pathology 18413 18417	FISH
R106	HappensAtOnDuring Arg1:T682 Arg2:T681	
T683	RadPathResult 18457 18465	Negative
R107	ResultOfTest Desc:T683 Test:T682	
T684	SectionSkip 18524 19308;19311 21139	RESULT:  Number of Observers: 2  Number of tumor cells assessed: 50  Mean HER2 signals/nucleus: 2.8  Mean Centromere 17 signals/nucleus: 2.5  Avg. Ratio of HER2: Cent17: 1.1    ISCN:  nuc ish 17p11.1q11.1(CEP17x2.5), 17q11.2q12(LSIHER-2/neux2.8)      06/20/17 Core-Biopsy of L breast   FINAL PATHOLOGIC DIAGNOSIS  Left breast, ultrasound-guided core biopsy:   1. Invasive ductal carcinoma; see comment.  2. Ductal carcinoma in situ, intermediate nuclear grade, cribriform  pattern with focal comedo necrosis.   3. Microcalcification associated with ductal carcinoma in situ.     COMMENT:  Breast Needle Core Biopsy Tumor Synoptic Comment    - Invasive tumor type: Invasive ductal carcinoma.  - Invasive tumor size: 1.2 cm longest dimension in one core, with tumor  present in multiple cores.  - Invasive tumor grade (modified Bloom-Richardson): Final grading  should be based on excision specimen.     - Nuclear grade: 2 points.    - Mitotic count: July 12 HPF, 2 points.    - Glandular/tubular differentiation: 2 points.    - Total points/grade: 6 points= grade 2.  - Lymphovascular invasion: Not identified.  - Ductal carcinoma in situ: Present, cribriform pattern with comedo  necrosis.   - Ductal carcinoma in situ nuclear grade: Intermediate.  - Microcalcifications: Present, associated with DCIS.  - Lobular carcinoma in situ: Not present.    The test for estrogen receptors is positive. There is strong nuclear  staining in 100% of tumor cells. Internal positive control is present,  and external positive control is appropriate.    The test for progesterone receptors is positive. There is moderate to  strong nuclear staining in >95% of tumor cells. Internal positive  control is present, and external positive control is appropriate.    Result of HER2 test: This carcinoma is negative for HER2 oncoprotein  over-expression. The staining intensity of this carcinoma was 1 on a  scale of 0-3.    Ki-67 proliferation index: ~20%      06/20/2017 FNA L Axillary Node  Source of Specimen: Left axillary lymph node, fine needle aspiration    FINAL CYTOLOGIC DIAGNOSIS:  A. Lymph node, left axillary, ultrasound-guided fine needle aspiration:  Positive for metastatic carcinoma; see comment.     COMMENTS:   The aspirates are abundantly cellular and reveal scattered irregular  sheets of malignant cells, some forming glandular structures. The cells  have enlarged nuclei with irregular nuclear contours and scant to  moderate cytoplasm. The cell block sample is concordant. The findings  are consistent with metastatic carcinoma of the breast. See also the  corresponding left breast core biopsy (*****-*****).
A141	SectionSkipType T684 pathology_report
T685	Age 21184 21186	70
T686	ClinicalCondition 21210 21213	HTN
A142	ChronicVal T686 chronic
T687	ClinicalCondition 21215 21218	HLD
A143	ChronicVal T687 chronic
T688	Stage 21254 21257	IIA
T689	TNM 21258 21267	pT2(m)N1a
A144	HistoryVal T689 new
A145	EpisodeDescription T689 FirstOccurrence
T690	Histology 21277 21280	IDC
A146	HistoryVal T690 new
A147	EpisodeDescription T690 FirstOccurrence
T691	Site 21270 21276	breast
T692	Laterality 21268 21269	L
R108	LateralityOfSite Arg1:T692 Arg2:T691	
R109	SiteOf Arg1:T691 Arg2:T690	
T693	Size 21282 21288	3.9 cm
A148	HistoryVal T693 new
A149	EpisodeDescription T693 FirstOccurrence
T694	Grade 21296 21297	2
A150	HistoryVal T694 new
A151	EpisodeDescription T694 FirstOccurrence
T695	BiomarkerName 21299 21301	ER
A152	HistoryVal T695 new
A153	EpisodeDescription T695 FirstOccurrence
T696	BiomarkerName 21303 21305	PR
A154	HistoryVal T696 new
A155	EpisodeDescription T696 FirstOccurrence
T697	BiomarkerName 21307 21310	HER
A156	HistoryVal T697 new
A157	EpisodeDescription T697 FirstOccurrence
T698	BiomarkerResult 21301 21302	+
A158	HistoryVal T698 new
A159	EpisodeDescription T698 FirstOccurrence
A160	BiomarkerResultVal T698 Positive
T699	BiomarkerResult 21305 21306	+
A161	HistoryVal T699 new
A162	EpisodeDescription T699 FirstOccurrence
A163	BiomarkerResultVal T699 Positive
T700	BiomarkerResult 21310 21311	-
A164	HistoryVal T700 new
A165	EpisodeDescription T700 FirstOccurrence
A166	BiomarkerResultVal T700 Negative
T701	Pathology 21317 21321	FISH
A167	IntentVal T701 diagnosis
T702	RadPathResult 21328 21331	1.1
R110	ResultOfTest Desc:T702 Test:T701	
R111	BiomarkerRel Arg1:T698 Arg2:T695	
R112	BiomarkerRel Arg1:T699 Arg2:T696	
R113	BiomarkerRel Arg1:T700 Arg2:T697	
T703	GenomicTest 21343 21353	mammaprint
A168	IntentVal T703 others
A169	GenomicTestType T703 GeneExpression
T704	GenomicTestResult 21333 21342	high-risk
A170	GenomicTestType T704 GeneExpression
R114	ResultOfTest Desc:T704 Test:T703	
T705	Datetime 21359 21367	08/18/17
T706	ProcedureName 21378 21390	mastectomies
A171	IntentVal T706 treatment-curative
A172	TreatmentTypeVal T706 local
A173	TreatmentCategory T706 Others
T707	Site 21368 21377	bilateral
R115	SiteOf Arg1:T707 Arg2:T706	
R116	HappensAtOnDuring Arg1:T706 Arg2:T705	
T708	ProcedureName 21410 21413	LND
A174	IntentVal T708 staging
A175	TreatmentTypeVal T708 local
A176	TreatmentCategory T708 Others
T709	Site 21401 21409	axillary
T710	Laterality 21396 21400	left
R117	LateralityOfSite Arg1:T710 Arg2:T709	
R118	SiteOf Arg1:T709 Arg2:T708	
T711	LymphNodeInvolvement 21419 21427	2/12 LN+
A177	HistoryVal T711 new
A178	EpisodeDescription T711 FirstOccurrence
R119	TestOrProcedureReveals Test:T708 Desc:T711	
T712	Stage 21487 21490	IIA
A179	HistoryVal T712 new
A180	EpisodeDescription T712 FirstOccurrence
T713	LymphNodeInvolvement 21530 21547	2 out of 12 nodes
A181	HistoryVal T713 new
A182	EpisodeDescription T713 FirstOccurrence
T714	ProcedureName 21582 21594	mastectomies
A183	IntentVal T714 treatment-curative
A184	TreatmentTypeVal T714 local
A185	TreatmentCategory T714 Others
T715	Site 21572 21581	bilateral
R120	SiteOf Arg1:T715 Arg2:T714	
T716	ClinicalCondition 21619 21632	breast cancer
T717	GenomicTest 21667 21677	mammaprint
A186	IntentVal T717 others
A187	GenomicTestType T717 GeneExpression
T718	Stage 21607 21612	early
R121	TumorDesc TumorDetails:T716 Desc:T718	
T719	Histology 21491 21494	IDC
A188	HistoryVal T719 new
A189	EpisodeDescription T719 FirstOccurrence
T720	LymphNodeInvolvement 21638 21646	positive
A190	HistoryVal T720 new
A191	EpisodeDescription T720 FirstOccurrence
R122	TumorDesc TumorDetails:T716 Desc:T720	
R123	TumorDesc TumorDetails:T716 Desc:T712	
R124	TumorDesc TumorDetails:T716 Desc:T719	
R125	TumorDesc TumorDetails:T716 Desc:T713	
R126	TestOrProcedureConductedForProblem Test:T717 Prob:T716	
T721	GenomicTestResult 21763 21772	high-risk
A192	GenomicTestType T721 GeneExpression
T722	GenomicTest 21739 21749	Mammaprint
A193	IntentVal T722 others
A194	GenomicTestType T722 GeneExpression
R127	TestOrProcedureConductedForProblem Test:T722 Prob:T716	
R128	ResultOfTest Desc:T721 Test:T722	
T723	TreatmentType 21813 21825	chemotherapy
A195	NegationModalityVal T723 hypothetical_in_future
A196	TreatmentTypeVal T723 adjuvant
A197	TreatmentIntentVal T723 curative
T724	MedicationName 21855 21874	aromatase inhibitor
A198	TreatmentTypeVal T724 adjuvant
A199	TreatmentIntentVal T724 curative
A200	TreatmentCategory T724 AntiNeoPlastics
T725	TreatmentType 21940 21952	chemotherapy
A201	NegationModalityVal T725 hypothetical_in_future
A202	TreatmentTypeVal T725 adjuvant
A203	TreatmentIntentVal T725 curative
T726	MedicationName 22002 22004	AC
A204	NegationModalityVal T726 hypothetical_in_future
A205	TreatmentTypeVal T726 adjuvant
A206	TreatmentIntentVal T726 curative
A207	TreatmentCategory T726 AntiNeoPlastics
T727	MedicationName 22010 22020	paclitaxel
A208	NegationModalityVal T727 hypothetical_in_future
A209	TreatmentTypeVal T727 adjuvant
A210	TreatmentIntentVal T727 curative
A211	TreatmentCategory T727 AntiNeoPlastics
R129	TreatmentAdministeredForProblem Treatment:T723 Prob:T721	
T728	Symptom 22090 22097	fatigue
A212	NegationModalityVal T728 hypothetical_in_future
T729	Symptom 22099 22102	n/v
A213	NegationModalityVal T729 hypothetical_in_future
T730	Symptom 22108 22117	hair loss
A214	NegationModalityVal T730 hypothetical_in_future
T731	TreatmentType 22066 22078	chemotherapy
A215	NegationModalityVal T731 hypothetical_in_future
A216	TreatmentTypeVal T731 adjuvant
A217	TreatmentIntentVal T731 curative
R130	ConditionOrTreatmentCausesProblem Treatment:T731 Prob:T728	
R131	ConditionOrTreatmentCausesProblem Treatment:T731 Prob:T729	
R132	ConditionOrTreatmentCausesProblem Treatment:T731 Prob:T730	
T732	Datetime 22249 22259	10/18/2017
T733	Radiology 22310 22313	TTE
A218	IntentVal T733 treatment-others
T734	Symptom 22334 22358	cardiotoxic side effects
A219	NegationModalityVal T734 hypothetical_in_future
T735	TreatmentType 22272 22284	chemotherapy
A220	NegationModalityVal T735 planned_in_future
A221	TreatmentContinuityVal T735 planned
A222	TreatmentTypeVal T735 adjuvant
A223	TreatmentIntentVal T735 curative
R133	BeginsOnOrAt Arg1:T735 Arg2:T732	
T736	MedicationName 22365 22378	anthracycline
A224	NegationModalityVal T736 planned_in_future
A225	TreatmentContinuityVal T736 planned
A226	TreatmentTypeVal T736 adjuvant
A227	TreatmentIntentVal T736 curative
A228	TreatmentCategory T736 AntiNeoPlastics
R134	ConditionOrTreatmentCausesProblem Treatment:T736 Prob:T734	
R135	TestOrProcedureConductedForProblem Test:T733 Prob:T734	
T737	ProcedureName 22380 22389	IV access
T738	ClinicalCondition 22481 22493	breast cance
A229	ExperiencerVal T738 family
T739	PatientCharacteristics 22543 22558	Jewish heritage
T740	TumorCharacteristics 22584 22597	BRCA positive
A230	NegationModalityVal T740 uncertain_in_present
T741	GenomicTest 22674 22689	genetic testing
A231	GenomicTestType T741 Unclear
T742	MedicationName 22745 22747	AC
A232	NegationModalityVal T742 planned_in_future
A233	TreatmentContinuityVal T742 planned
A234	TreatmentTypeVal T742 adjuvant
A235	TreatmentIntentVal T742 curative
A236	TreatmentCategory T742 AntiNeoPlastics
T743	MedicationName 22750 22760	paclitaxel
A237	NegationModalityVal T743 planned_in_future
A238	TreatmentContinuityVal T743 planned
A239	TreatmentTypeVal T743 adjuvant
A240	TreatmentIntentVal T743 curative
A241	TreatmentCategory T743 AntiNeoPlastics
T744	Datetime 22783 22793	10/18/2017
R136	BeginsOnOrAt Arg1:T743 Arg2:T744	
R137	BeginsOnOrAt Arg1:T742 Arg2:T744	
T745	Radiology 22826 22829	TTE
A242	NegationModalityVal T745 planned_in_future
A243	IntentVal T745 treatment-others
T746	ProcedureName 22872 22886	port placement
A244	NegationModalityVal T746 planned_in_future
A245	IntentVal T746 treatment-others
A246	TreatmentTypeVal T746 others
A247	TreatmentCategory T746 Others
A248	IntentVal T737 treatment-others
A249	TreatmentTypeVal T737 others
A250	TreatmentCategory T737 Others
T747	TreatmentType 22727 22739	chemotherapy
A251	NegationModalityVal T747 planned_in_future
A252	TreatmentContinuityVal T747 planned
A253	TreatmentTypeVal T747 adjuvant
A254	TreatmentIntentVal T747 curative
T751	Radiology 10369 10379	Ultrasound
A256	IntentVal T751 diagnosis
T752	Radiology 9800 9809	Mammogram
A257	IntentVal T752 diagnosis
T753	Datetime 9791 9799	06/20/17
R141	HappensAtOnDuring Arg1:T752 Arg2:T753	
T754	Pathology 9577 9606	ultrasound-guided core biopsy
A258	IntentVal T754 diagnosis
T755	Site 9615 9656	breast mass, at 3:00, 8cm from the nipple
T756	Laterality 9610 9614	left
R142	LateralityOfSite Arg1:T756 Arg2:T755	
R143	SiteOf Arg1:T755 Arg2:T754	
T757	Pathology 9723 9734;9737 9747	fine needle aspiration
A259	IntentVal T757 diagnosis
T758	Site 9765 9784	axillary lymph node
T759	Laterality 9760 9764	left
R144	LateralityOfSite Arg1:T759 Arg2:T758	
R145	SiteOf Arg1:T758 Arg2:T757	
T748	SectionSkip 11113 11417	IMPRESSION:   Left breast: Highly suggestive of malignancy (BI-RADS 5).  Recommendations:  Recommend ultrasound-guided core biopsy of left breast mass, at 3:00, 8cm from the nipple as the more suspicious of the two ultrasound masses.  Recommend fine needle aspiration of abnormal left axillary lymph node
A255	SectionSkipType T748 copy_forward
T749	SectionSkip 11426 11677;11680 11934	05/27/2017 Mammogram  IMPRESSION  Finding 1:Solid mass in the left breast at 3 o'clock is suspicious.  Ultrasound-guided core biopsy is recommended.     Finding 2:Solid mass in the left breast at 1 o'clock is suspicious.  Ultrasound-guided core biopsy is recommended.     Finding 3:Prominent lymph node in the left axilla is suspicious.  Ultrasound-guided core biopsy is recommended. The referring physician was  notified of these results by fax.    BI-RADS Category 4 : Suspicious  4C - Moderate Suspicion
A260	SectionSkipType T749 radiology_report
T750	Datetime 11940 11950	01/25/2017
T760	Radiology 11951 11960	Mammogram
T761	RadPathResult 12002 12012	malignancy
A261	NegationModalityVal T761 negated
A262	RadPathResultVal T761 NoDisease
R138	ResultOfTest Desc:T761 Test:T760	
T762	GenomicTest 12314 12324	Mammaprint
A263	GenomicTestType T762 GeneExpression
T763	GenomicTestResult 12326 12335	High-Risk
A264	GenomicTestType T763 GeneExpression
R139	ResultOfTest Desc:T763 Test:T762	
R140	HappensAtOnDuring Arg1:T760 Arg2:T750	
R146	SizeOf Arg1:T504 Arg2:T499	
R147	SizeOf Arg1:T576 Arg2:T575	
T764	PatientCharacteristics 2868 2883	Jewish heritage
R148	SiteOf Arg1:T598 Arg2:T596	
T765	ProcedureName 3359 3371	foot surgery
R149	ConditionOrTreatmentCausesProblem Treatment:T765 Prob:T611	
T766	ClinicalCondition 4379 4387	leukemia
A265	ExperiencerVal T766 family
T767	ClinicalCondition 4389 4400	lung cancer
A266	ExperiencerVal T767 family
T768	ClinicalCondition 4402 4405	HCC
A267	ExperiencerVal T768 family
T769	ClinicalCondition 4410 4426	laryngeal cancer
A268	ExperiencerVal T769 family
T770	ClinicalCondition 4287 4294;4309 4315	ovarian cancer
A269	NegationModalityVal T770 negated
T771	ClinicalCondition 4298 4315	pancreatic cancer
A270	NegationModalityVal T771 negated
A271	ExperiencerVal T771 family
A272	ExperiencerVal T770 family
T772	Symptom 6146 6153	malaise
A273	NegationModalityVal T772 negated
T773	Symptom 6154 6161	fatigue
A274	NegationModalityVal T773 negated
T774	Symptom 6166 6177	weight loss
A275	NegationModalityVal T774 negated
T775	Symptom 6200 6210	congestion
A276	NegationModalityVal T775 negated
T776	Symptom 6215 6225	sinus pain
A277	NegationModalityVal T776 negated
T777	Symptom 6249 6262	double vision
A278	NegationModalityVal T777 negated
T778	Symptom 6292 6297	cough
A279	NegationModalityVal T778 negated
T779	Symptom 6299 6316	sputum production
A280	NegationModalityVal T779 negated
T780	Symptom 6321 6340	shortness of breath
A281	NegationModalityVal T780 negated
T781	Symptom 6374 6384	chest pain
A282	NegationModalityVal T781 negated
T782	Symptom 6386 6398	palpitations
A283	NegationModalityVal T782 negated
T783	Symptom 6403 6415	leg swelling
A284	NegationModalityVal T783 negated
T784	Symptom 6550 6558	myalgias
A285	NegationModalityVal T784 negated
T785	Symptom 6581 6585	rash
A286	NegationModalityVal T785 negated
T786	Symptom 6480 6488	diarrhea
A287	NegationModalityVal T786 negated
T787	Symptom 6466 6478	constipation
A288	NegationModalityVal T787 negated
T788	Symptom 6493 6502	heartburn
A289	NegationModalityVal T788 negated
T789	Symptom 6450 6464	abdominal pain
A290	NegationModalityVal T789 negated
T790	Symptom 6536 6545	back pain
A291	NegationModalityVal T790 negated
T791	Symptom 6722 6731	dizziness
A292	NegationModalityVal T791 negated
T792	Symptom 6749 6757	weakness
A293	NegationModalityVal T792 negated
T793	Symptom 6762 6771	headaches
A294	NegationModalityVal T793 negated
T794	Symptom 6733 6747	focal weakness
A295	NegationModalityVal T794 negated
T10	SectionSkip 8139 9734;9737 10365	Radiology:  06/20/17 Ultrasound, Left  Mammographic Findings:  There are scattered areas of fibroglandular density.    At the site of the palpable lump in the outer central left breast, middle depth, marked by BB  there is a 15 mm irregular obscured mass with associated architectural distortion.    No single mammographic correlate for site of palpable concern in the left breast marked by more anterior BB.  However, there are innumerable small masses centered in the outer central left breast with some extension into upper outer quadrant.  There is also associated nipple retraction.    Ultrasound Findings:  There is a 11 x 12 x 12 mm irregular, not-parallel, heterogeneous hypoechoic solid mass with angular margins, in the outer central left breast, at approximately 3 o'clock, 8 cm from nipple, corresponding to the mammographic mass with associated architectural distortion and one of the palpable lumps. Vascularity is present.    There is a 15 x 12 x 14 mm irregular solid mass with angular margins, in the upper outer left breast, at approximately 2 o'clock, 3 cm from nipple, which contains calcifications, likely within the large area of multiple small masses seen at mammography.    There are at least two abnormal left axillary lymph nodes at 2:00, 20cm from the nipple, with coritcal thickness measuring up to 9mm.    IMPRESSION:   Left breast: Highly suggestive of malignancy (BI-RADS 5).    Recommendations:  Recommend ultrasound-guided core biopsy of left breast mass, at 3:00, 8cm from the nipple as the more suspicious of the two ultrasound masses.    Recommend fine needle aspiration of abnormal left axillary lymph node.      06/20/17 Mammogram, Left  Mammographic Findings:  There are scattered areas of fibroglandular density.    At the site of the palpable lump in the outer central left breast, middle depth, marked by BB  there is a 15 mm irregular obscured mass with associated architectural distortion.    No single mammographic correlate for site of palpable concern in the left breast marked by more anterior BB.  However, there are innumerable small masses centered in the outer central left breast with some extension into upper outer quadrant.  There is also associated nipple retraction.
A118	SectionSkipType T10 radiology_report
T11	SectionSkip 17531 18520	- AJCC/UICC stage: pT2(m)N1a.    - Tumor biomarker (ER/PR/HER2/Ki-67) status:   Immunohistochemical tests for estrogen and progesterone receptors, HER2  and Ki-67 were performed by manual morphometry on block ***** (tumor #3,  the largest tumor).    The test for estrogen receptors is positive. There is strong nuclear  staining in >95% of tumor cells. Internal positive control is present,  and external positive control is appropriate.    The test for progesterone receptors is positive. There is strong  nuclear staining in >95% of tumor cells. Internal positive control is  present, and external positive control is appropriate.    Result of HER2 test: This carcinoma is equivocal for HER2 oncoprotein  over-expression. The staining intensity of this carcinoma was 2 on a  scale of 0-3.    Ki-67 proliferation index: 20 to 30%      08/18/2017 HER2 Gene Amplification Testing by FISH  LABORATORY PHYSICIAN INTERPRETATION:  Negative: Tumor cells showing no amplification of HER2 (ERBB2).
A119	SectionSkipType T11 pathology_report
T671	Pathology 1493 1496	IHC
T795	RadPathResult 1490 1492	1+
R150	ResultOfTest Desc:T795 Test:T671	
T796	Grade 1950 1951	2
T797	Grade 1956 1957	1
A122	HistoryVal T797 new
A296	EpisodeDescription T797 FirstOccurrence
A297	HistoryVal T796 new
A298	EpisodeDescription T796 FirstOccurrence
A299	HistoryVal T575 new
A300	EpisodeDescription T575 FirstOccurrence
R151	TestOrProcedureReveals Test:T567 Desc:T796	
R152	TestOrProcedureReveals Test:T567 Desc:T797	
T798	ProcedureName 2483 2490	surgery
A301	IntentVal T798 treatment-curative
A302	TreatmentTypeVal T798 local
A303	TreatmentCategory T798 Others
A304	IsTumorRemaining T798 no
R153	TestOrProcedureConductedForProblem Test:T798 Prob:T582	
R154	TestOrProcedureConductedForProblem Test:T798 Prob:T585	
T799	ClinicalCondition 2830 2836	cancer
A305	NegationModalityVal T799 negated
A306	ExperiencerVal T799 family
T800	Site 2819 2829	pancreatic
T801	Site 2808 2815	ovarian
R155	SiteOf Arg1:T800 Arg2:T799	
R156	SiteOf Arg1:T801 Arg2:T799	
T802	Radiology 12034 12045	mammography
A307	NegationModalityVal T802 planned_in_future
A308	IntentVal T802 screening
T803	Frequency 12017 12023	Annual
R157	Temporal Arg1:T802 Arg2:T803	
T804	Duration 12049 12055	1 year
R158	HappensAfter Arg1:T802 Arg2:T804	
R159	SizeOf Arg1:T693 Arg2:T690	
R160	TestOrProcedureConductedForProblem Test:T741 Prob:T738	
T805	hpi_start 2 7	Chief
T806	hpi_end 2934 2935	.
T807	ap_start 21146 21156	Assessment
T808	ap_end 22993 23006	satisfaction.
